Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2021 1
2022 2
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
From Emergence to Endemicity: A Comprehensive Review of COVID-19.
Naik R, Avula S, Palleti SK, Gummadi J, Ramachandran R, Chandramohan D, Dhillon G, Gill AS, Paiwal K, Shaik B, Balachandran M, Patel B, Gurugubelli S, Mariswamy Arun Kumar AK, Nanjundappa A, Bellamkonda M, Rathi K, Sakhamuri PL, Nassar M, Bali A. Naik R, et al. Cureus. 2023 Oct 31;15(10):e48046. doi: 10.7759/cureus.48046. eCollection 2023 Oct. Cureus. 2023. PMID: 37916248 Free PMC article. Review.
Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.
Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y, Murray KS. Linehan J, et al. Eur Urol Focus. 2023 Nov;9(6):1052-1058. doi: 10.1016/j.euf.2023.05.012. Epub 2023 May 30. Eur Urol Focus. 2023. PMID: 37263827
First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors.
Jacob JM, Woldu SL, Linehan J, Labbate C, Rose KM, Sexton WJ, Tachibana I, Kaimakliotis H, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour SB, Quek ML, Johnson B, O'Donnell M, Eisner BH, Feldman AS, Murray KS, Matin SF, Lotan Y, Dickstein RJ. Jacob JM, et al. Urol Oncol. 2024 Jan;42(1):20.e17-20.e23. doi: 10.1016/j.urolonc.2023.07.004. Epub 2023 Jul 28. Urol Oncol. 2024. PMID: 37517898
The Predictive Value of False-Positive ForeseeHome Alerts in the ALOFT Study.
Ho AC, Schechet SA, Mathai M, Reddy S, Elman MJ, Garfinkel RA, Ladd B, Wagner AL, Sanborn GE, Jacobs JH, Busquets MA, Chew EY. Ho AC, et al. Ophthalmol Retina. 2023 Feb;7(2):196-198. doi: 10.1016/j.oret.2022.10.009. Epub 2022 Oct 22. Ophthalmol Retina. 2023. PMID: 36280205 Free article. No abstract available.
Corrigendum to "Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes" [Eur. Urol. Focus (2023)].
Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y, Murray KS. Linehan J, et al. Eur Urol Focus. 2024 Jan;10(1):211. doi: 10.1016/j.euf.2023.08.006. Epub 2023 Aug 26. Eur Urol Focus. 2024. PMID: 37640582 No abstract available.
A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.
Pachl J, Svoboda P, Jacobs F, Vandewoude K, van der Hoven B, Spronk P, Masterson G, Malbrain M, Aoun M, Garbino J, Takala J, Drgona L, Burnie J, Matthews R; Mycograb Invasive Candidiasis Study Group. Pachl J, et al. Clin Infect Dis. 2006 May 15;42(10):1404-13. doi: 10.1086/503428. Epub 2006 Apr 12. Clin Infect Dis. 2006. PMID: 16619152 Free article. Clinical Trial.